Invesco Ltd. Alx Oncology Holdings Inc Transaction History

Invesco Ltd.

$460 Billion
Q2 2024

A detailed history of Invesco Ltd. transactions in Alx Oncology Holdings Inc stock. As of the latest transaction made, Invesco Ltd. holds 10,290 shares of ALXO stock, worth $22,843. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,290

Holding current value

$22,843

% of portfolio

0.0%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$5.84 - $17.56 $60,093 - $180,692	10,290 New	10,290 $62,000
Q4 2023 Feb 12, 2024	BUY	$4.81 - $15.38 $1.85 Million - $5.92 Million	385,232 New	385,232 $5.74 Million
Q2 2022 Aug 15, 2022	SELL	$5.89 - $19.46 $3.79 Million - $12.5 Million	-643,487 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$13.65 - $22.06 $185,162 - $299,243	13,565 Added 2.15%	643,487 $10.9 Million
Q4 2021 Feb 14, 2022	BUY	$21.49 - $74.4 $2.47 Million - $8.56 Million	115,107 Added 22.36%	629,922 $13.5 Million
Q3 2021 Nov 15, 2021	BUY	$52.51 - $80.91 $26.6 Million - $41.1 Million	507,399 Added 6841.95%	514,815 $38 Million
Q2 2021 Aug 17, 2021	BUY	$52.2 - $75.23 $220,545 - $317,846	4,225 Added 132.4%	7,416 $406,000
Q1 2021 May 17, 2021	BUY	$62.84 - $87.68 $200,522 - $279,786	3,191 New	3,191 $235,000

Others Institutions Holding ALXO

# of Institutions

122

Shares Held

40.7M

Call Options Held

518K

Put Options Held

142K

Ven Bio Partners LLC San Francisco, CA

9.7M
Shares

$21.5 Million
33.06% of portfolio
Vivo Capital, LLC Palo Alto, CA

4.22M
Shares

$9.37 Million
3.76% of portfolio
Redmile Group, LLC San Francisco, CA

4.04M
Shares

$8.96 Million
1.59% of portfolio
Vestal Point Capital, LP New York, NY

3.6M
Shares

$7.99 Million
1.62% of portfolio
Black Rock Inc. New York, NY

2.69M
Shares

$5.97 Million
0.0% of portfolio

View Full List

About ALX ONCOLOGY HOLDINGS INC

Ticker ALXO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,747,100
Market Cap $90.5M
Description
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...

More about ALXO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account